

ICD-10 Coding Guide for VASCEPA® (icosapent ethyl)

This guide may assist you in completing payer forms for VASCEPA. This table is for informational purposes only. Please visit CMS.gov or other payers' websites to obtain additional guidance on other processes related to billing and coding.

INDICATION

VASCEPA is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with TG \geq 150 mg/dL and established CVD or diabetes mellitus and \geq 2 additional CVD risk factors.

These codes are not all-inclusive. Appropriate codes can vary by patient, payer, and setting of care. The provider is responsible for ensuring correct coding. Please check with the payer to verify codes and special billing requirements. Amarin does not make any representation or guarantee concerning reimbursement or coverage.

ESTABLISHED CARDIOVASCULAR DISEASE¹

Code	Description
I21.0	ST elevation (STEMI) myocardial infarction of anterior wall
I21.1	ST elevation (STEMI) myocardial infarction of inferior wall
I21.2	ST elevation (STEMI) myocardial infarction of other sites
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site
I21.4	Non-ST elevation (NSTEMI) myocardial infarction
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
I25.2	Old myocardial infarction
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris
I25.83	Coronary atherosclerosis due to lipid rich plaque
I25.84	Coronary atherosclerosis due to calcified coronary lesion
I63.9	Cerebral infarction, unspecified
I67.9	Cerebrovascular disease, unspecified
I73.9	Peripheral vascular disease, unspecified
Z95.1	Presence of aortocoronary bypass graft
Z98.61	Coronary angioplasty status

DIABETES AND 2 OR MORE ADDITIONAL RISK FACTORS¹

Code	Description
E10	Type 1 diabetes mellitus
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication
E11	Type 2 diabetes mellitus
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease
E66.01	Morbid (severe) obesity due to excess calories
E66.9	Obesity, unspecified
E78.0	Pure hypercholesterolemia
E78.2	Mixed hyperlipidemia
E78.5	Hyperlipidemia, unspecified
I10	Essential (primary) hypertension
N18.9	Chronic kidney disease, unspecified
R79.82	Elevated C-reactive protein (CRP)
Z72.0	Tobacco use
Z82.3	Family history of stroke
Z82.49	Family history of ischemic heart disease and other diseases of the circulatory system

The daily dose of VASCEPA is 4 g per day taken as two 1-g or four 0.5-g capsules BID with food.²

INDICATIONS AND LIMITATIONS OF USE

- VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (\geq 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
- VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (\geq 500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

IMPORTANT SAFETY INFORMATION

- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

Please see additional Important Safety Information for VASCEPA on the back. Please see accompanying full Prescribing Information for VASCEPA or go to www.vascepahcp.com.

Vascepa
(icosapent ethyl)



THE NEXT LEVEL OF HEART PROTECTION

ICD-10 Coding Guide for VASCEPA®

IMPORTANT SAFETY INFORMATION (cont'd)

- VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter
- It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur
- VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin
- Common adverse reactions in the cardiovascular outcomes trial (incidence $\geq 3\%$ and $\geq 1\%$ more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)
- Common adverse reactions in the hypertriglyceridemia trials (incidence $\geq 1\%$ more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)
- Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see additional Important Safety Information for VASCEPA on the front.

Please see accompanying full Prescribing Information for VASCEPA or go to www.vascepahcp.com.

References: **1.** Centers for Medicare & Medicaid Services. 2020 ICD-10-CM. 2020 Code Descriptions in Tabular Order. <https://www.cms.gov/Medicare/Coding/ICD10/2020-ICD-10-CM>. Updated January 27, 2020. Accessed March 4, 2020. **2.** VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2019.

www.vascepahcp.com



VASCEPA is a registered trademark of the Amarin group of companies.
©2020 Amarin Pharma, Inc. Bridgewater, NJ 08807 All rights reserved. VAS-02496 03/20

Vascepa[®]
(icosapent ethyl)



THE NEXT LEVEL OF HEART PROTECTION